Регидрон

Quick links to important sections

Регидрон

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Регидрон

What is Regidron?

Property Description
Active Ingredients Dextrose, Potassium Chloride, Sodium Chloride, Sodium Citrate
Form Powder for Oral Solution
Pharmacological Class Regulator of water-electrolyte balance (Oral Rehydration Agent)
General Purpose Compensation for fluid and salt loss (Dehydration)
Origin Synthetic (Combined Preparation)

What Type of Medicine is Regidron (Регидрон)?

Regidron is formally categorized as a combined oral rehydration agent (ORS), belonging to the pharmacological class of Regulators of water-electrolyte balance. This synthetic preparation is designed to be dissolved in water and administered via the oral route. The product’s composition is consistent with the essential criteria for effective Oral Rehydration Solutions as defined by international health bodies. This confirms that the formulation is a foundational treatment for rapidly restoring the body’s fluid and salt composition, a practice clinically recognized for its high efficacy.

The core therapeutic purpose of the product is to counteract the effects of acute fluid loss. Unlike simple soft drinks or plain water, Regidron’s powder form ensures a precisely measured dose of components that meets recognized standards for effective rehydration. Its goal is to compensate for dehydration and electrolyte depletion, often arising from episodes of infectious diarrhea or persistent vomiting.

What is the Composition of Regidron and How Does it Work Generally?

The core of Regidron is a precisely balanced blend of four active ingredients: Dextrose (Glucose), Potassium Chloride, Sodium Chloride, and Sodium Citrate. These components provide the critical electrolytes necessary to stabilize the body’s internal environment following fluid loss. Glucose is crucial in ORS for enhancing the absorption of sodium and water in the small intestine. This means the presence of Dextrose makes the solution significantly more effective than salt water alone.

The inclusion of Dextrose is integral to the mechanism, actively facilitating the co-transport of sodium ions and water across the intestinal wall. Additionally, the Citrate component helps manage and correct the state of metabolic acidosis (excess acidity) that commonly accompanies severe fluid depletion. This combined action ensures a comprehensive restoration of the body's ionic balance.

What is the General Therapeutic Purpose of Oral Rehydration Agents?

The primary general therapeutic purpose is the efficient replacement of lost fluid and electrolyte volume to avert severe complications of dehydration. Oral rehydration solutions are utilized to provide the necessary minerals that the body loses quickly during periods of severe gastrointestinal distress. By effectively restoring these fundamental components, Regidron helps maintain the critical electrical gradients across cell membranes, ensuring supportive care for vital organ functions during recovery from acute water and salt depletion.

What side effects are possible with Регидрон?

Possible Side Effects and Safety Information

The following information details the officially documented adverse effects and safety constraints for the oral rehydration agent Регидрон (Regidron), based strictly on government regulatory documents.


Adverse Reactions and System-Organ Classes

The majority of regulatory documents state that adverse effects are not expected when the solution is correctly prepared and used. Specific frequency categories (e.g., Common, Rare) are generally not assigned. Potential adverse reactions listed in regulatory indices are grouped by System-Organ Class:

  • Immune System Disorders: Hypersensitivity (Allergy).
  • Nervous System Disorders: Convulsions, Dizziness, Irritability.
  • Cardiovascular Effects: Tachycardia (fast heart rate), High blood pressure.
  • General Disorders: Swelling of feet or lower legs, Puffy eyelids.

Serious Safety Considerations

Salt Toxicity (Hypernatremia): The most significant safety risk is linked to incorrect preparation, such as using too little water. This can lead to severe electrolyte imbalance, manifesting as confusion and potentially causing kidney damage. Overdosage requires immediate evaluation of serum electrolytes.

Exposure-Related Signs: The occurrence of puffy eyelids or swelling during treatment is noted as a sign of potential over-hydration or electrolyte excess. If this occurs, the oral rehydration solution should be temporarily stopped.


Safety-Related Restrictions (Contraindications)

This agent is formally contraindicated and should not be used in the following conditions:

  • Severe Dehydration (requires intravenous fluid therapy).
  • Intestinal Obstruction.
  • Known Hypersensitivity to any of the ingredients.
  • Conditions affecting sugar absorption, such as Rare Glucose-Galactose Malabsorption.

Population-Specific Oversight

Treatment must be supervised by a physician for patients with pre-existing conditions that affect electrolyte management, including renal impairment (kidney disease), hepatic impairment (liver disease), and diabetes. Use in children under 1 year should only occur on medical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation confirms that the primary clinical manifestations of overdosage involve critical disturbances in water-electrolyte balance. Overdosage, particularly in patients with impaired renal function or resulting from using an over-concentrated solution, may lead to severe hypernatraemia (excess sodium) and hyperkalaemia (excess potassium).

Severe hypernatraemia has been associated with life-threatening outcomes, including death, when the product is prepared with too little water. Monitoring and evaluation are particularly important in the very young and in patients with severe hepatic or renal failure due to the heightened risk of these electrolyte abnormalities.

Emergency Actions Mandated by Regulators:

  • Medical supervision is necessary if renal disease (e.g., anuria or prolonged oliguria) is present, or if there is severe and persistent diarrhoea/vomiting or an inability to retain fluids.
  • If overdosage is suspected, serum electrolytes should be evaluated immediately by a healthcare professional.
  • Management requires taking appropriate steps to correct any abnormalities detected and involves continuous monitoring until a return to normal physiological levels is established.

No specific antidote is explicitly documented; management is supportive and focused on correcting the underlying electrolyte imbalance.

Therapeutic Uses of Регидрон

What Regidron treats: main uses and benefits

Regidron is commonly applied in situations involving acute loss of water and essential electrolytes, primarily due to severe gastrointestinal episodes such as gastroenteritis (stomach flu) and cholera, marked by frequent, watery diarrhea and vomiting. This type of solution is used for managing the replacement of lost fluid and electrolytes, which supports the body and may assist with maintaining functional stability and addressing the effects of volume depletion.

The rehydration agent is relevant in conditions characterized by periods of heightened symptoms and is commonly used to help with acute episodes of diarrhea, vomiting, and other causes of volume depletion. It addresses the resulting symptomatic cluster of dehydration, including intense thirst, dryness of the mouth and mucous membranes, and decreased urination. The balanced composition is intended for easing symptoms related to systemic imbalance. It provides essential supportive care that helps ease the overall burden of these manifestations and contributes to improved comfort during symptomatic periods.

This oral rehydration agent offers crucial relevance for all age groups, particularly children and infants, who are highly vulnerable to the consequences of fluid depletion. The use of this agent in the community setting provides support that helps ease the overall symptom burden and assists with maintaining functional stability.


Quick Fact: Relief for Intense Thirst

Addressing symptoms associated with fluid loss is relevant for easing the acute physical discomfort associated with pronounced dehydration symptoms, such as the persistent feeling of intense thirst and dryness.


Eligibility and Restrictions for Use

Who Can and Cannot Use Regidron?

This section outlines the official population eligibility and non-eligibility rules for Regidron (Oral Rehydration Salts) as documented in regulatory sources.

Regidron is permitted for use across all standard age groups, including infants, children, adolescents, adults, and older adults. Use is also generally permitted during pregnancy and lactation when clinically indicated for fluid and electrolyte replacement.

Absolute Contraindications (Do Not Use)

Regidron is contraindicated and must not be used in patients with the following conditions, as stated in official labeling:

  • Intestinal obstruction (ileus).
  • Unconsciousness or loss of consciousness (due to aspiration risk).
  • Severe renal impairment (anuria/oliguria).
  • Hyperkalemia (high serum potassium levels).
  • Glucose malabsorption.
  • Hypovolemic shock not caused by dehydration.

Conditional Use (Use with Caution)

Patients with certain underlying health issues may use the product, but require caution and monitoring as the electrolyte and glucose content may require adjustment or close medical oversight:

  • Diabetes mellitus.
  • Mild-to-moderate renal impairment.
  • Congestive heart failure (CHF) or hypertension.

What should I know about interactions with other medicines?

The interaction profile of Regidron is primarily defined by the pharmacodynamic properties of its electrolyte components and constraints related to its large-volume administration. Regulatory documentation highlights interactions with other medicines and important procedural restrictions.

Co-administration with potassium-sparing agents or other products containing potassium may result in an additive pharmacodynamic effect on serum potassium levels, increasing the risk of hyperkalemia. Caution is also noted with cardiac glycosides (e.g., Digoxin), as fluctuations in potassium concentration can influence their regulatory effect. Furthermore, the alkaline reaction of the solution should be considered when used with medicines whose absorption is dependent on a specific gastrointestinal pH value, potentially requiring adjustment in administration timing.

To prevent dilution and potential alteration of absorption kinetics, co-administration with other oral medicines must be separated by a time interval. A key procedural restriction noted in regulatory labeling is the prohibition against mixing the solution with liquids high in simple carbohydrates or fat, such as fruit juices or broth, as this disrupts the required osmolality and inhibits the solution's efficacy. The risk of electrolyte accumulation, specifically hypernatremia and hyperkalemia, is officially noted as a heightened concern for patients with impaired renal function.

Mechanism of Action

How Регидрон Works: Mechanism of Action

SGLT1 Co-Transport and Volume Dynamics

The primary mechanism involves the obligatory co-transport of Sodium ( Na^+) and Dextrose through the Sodium-Glucose Co-transporter 1 ( SGLT1) protein located on intestinal cells. This co-transport drives the transfer of solutes from the gut lumen into the circulation, which creates an osmotic gradient. Water passively follows this gradient, shifting fluid volume from the intestine into the blood plasma, thus influencing systemic water dynamics and circulating volume.


Modulation of Ionic and pH Balance

In parallel, the mechanism addresses specific biochemical deficits. The inclusion of Potassium ( K^+) and Chloride ( Cl^-) provides replacement electrolytes that influence cellular electrical potentials. Furthermore, the Citrate component is metabolized to generate bicarbonate ( HCO3^-). This crucial process actively consumes excess hydrogen ions ( H^+), leading to the modulation of systemic acid-base homeostasis. The combined action ensures the simultaneous engagement of mechanisms addressing fluid, ionic, and pH disturbances.

Dosage and Administration Information

Administration Route and Preparation

The medicine is strictly administered via the Oral Route, supplied as a powder that must be dissolved prior to use. Official instructions require the contents of the sachet to be reconstituted using a specific volume of newly boiled water, cooled to room temperature. It is a core instruction that the prepared solution must not be mixed with other liquids or ingredients, which could alter the essential electrolyte concentration.

Dosing and Schedule Protocol

Administration follows a two-phase dosing strategy to address fluid loss. The initial rehydration phase is a time-limited period, typically lasting 3 to 6 hours, during which a total volume of 50–100 mL/kg may be administered in frequent, small portions. The maintenance phase is demand-driven; the volume is administered (e.g., 200–400 mL for adults) following each loose stool or vomiting episode to replace ongoing losses.

Population Rules and Duration

For pediatric patients, the solution is delivered in smaller increments, such as 1–2 teaspoons at frequent intervals (e.g., every 5 to 10 minutes). If vomiting occurs during the rehydration period, the solution should be paused for 10 minutes and then resumed at a slower rate. The administration course is generally short-term, continuing until the signs of dehydration are resolved, and typically does not exceed 3 to 4 days.

Recent Clinical Evidence

Research evidence / Overview of studies for Regidron

Oral Rehydration Solutions (ORS), the class of product that Regidron belongs to, has been used in research exploring fluid and salt loss over many decades. This evidence helps show what has been observed so far regarding the use of these solutions. The research mainly explores how the symptoms of acute fluid depletion evolve in observed populations under various conditions.


Evidence for Acute Diarrhea and Gastroenteritis

Controlled clinical trials and systematic reviews were conducted for ORS in conditions characterized by periods of heightened symptoms, such as acute diarrhea and gastroenteritis. Research was evaluated in populations presenting with mild to moderate dehydration. Studies examined specific outcomes related to physical discomfort and systemic imbalance, such as the patient's total stool output volume, the overall duration of the diarrheal episode, and the rate of subsequent unscheduled visits to clinics or hospitals. However, studies comparing ORS directly to an inactive agent remain limited in many modern, resource-rich settings, as ethical considerations prevent withholding rehydration treatment from patients with clinical fluid loss.


Evidence for Severe Fluid Loss and Cholera-Related Dehydration

Research for severe fluid loss, including conditions such as cholera, is characterized by large-scale Randomized Controlled Trials (RCTs). These studies explored acute changes in patients who had experienced rapid fluid loss. The research in this area often focused on measured outcomes, including diarrhea-specific mortality rates and the overall requirement for fluid replacement through IV administration. This research describes patterns related to the measurement of intravenous fluid replacement requirements, which was observed in some studies.


Research in Special Populations and Long-Term Evidence

Oral rehydration therapy was evaluated in a wide range of populations, particularly children and infants. Research has explored short-term symptom changes in young children with acute episodes of diarrhea and vomiting. However, the research on Regidron, as an oral electrolyte solution formulation, primarily focuses on short-term observation intervals, typically 24 to 48 hours. Long-term effects are not fully established; there is limited information for long-term outcomes, such as the durability of the response or the potential for reducing the risk of recurrence months later.

Key Studies & References Glucose-Based Oral Rehydration Therapy: A Review of its Rationale, Efficacy, and Global Impact

Frequently Asked Questions (FAQ)

Common questions about Регидрон (FAQ)


Q: Can Rehydron be used for simple nausea without vomiting?

The primary therapeutic purpose of the product, according to official indications, is to correct fluid loss and electrolyte depletion. The product is designed to support the body when fluid and electrolyte losses need compensation, typically due to episodes of acute diarrhea or vomiting, or excessive sweating.


Q: What should be done if the taste of Rehydron seems unpleasant?

To maintain the regulated therapeutic concentration, official guidelines state that the solution should not be mixed with any other liquids, simple sugars, or flavorings. Altering the specific balance of electrolytes could inhibit the solution's efficacy, according to regulatory guidelines.


Q: Can Rehydron affect the action of antibiotics?

Official information indicates that the solution has an alkaline reaction, which may affect the absorption or efficacy of certain oral medicines. This is related to how the medicine’s absorption may depend on the pH level (acidity) of the stomach and digestive tract. To avoid potential effects, a time interval should separate the administration of the solution and other oral medications.


Q: Is Rehydron used only for diarrhea and vomiting, or are there other cases?

While often used for diarrhea and vomiting, official indications for oral rehydration agents cover electrolyte and fluid replacement when dehydration occurs. The indications include fluid loss due to excessive sweating or heat exhaustion.


Q: Can Rehydron be used by athletes after intensive workouts?

The labeled purpose of oral rehydration agents is to restore or prevent fluid and electrolyte loss caused by excessive sweating. This mechanism indicates its role in compensating for fluid and electrolyte losses that may occur due to intensive physical activity.


Q: Can Rehydron help with a hangover?

According to regulatory information, the therapeutic purpose is to compensate for fluid and electrolyte loss. Although hangovers are not a specific labeled indication, the solution is designed to address the symptoms of dehydration and electrolyte imbalance which may be associated with the consumption of alcohol.


Q: Can Rehydron be taken if you are taking diuretics?

Patients using diuretics, especially potassium-sparing diuretics, are advised to have medical oversight. Official regulatory information highlights that caution is necessary in these situations due to a potential increase in the risk of hyperkalemia (high serum potassium levels).


Q: Why do official documents mention caution regarding liver function?

Patients with hepatic impairment (liver disease) require medical oversight when using the solution. This requirement is linked to the metabolism of the citrate component, which is involved in correcting the body’s acid-base balance.


Q: What serious side effects require immediate medical attention?

Medical attention is necessary if symptoms of severe dehydration worsen or if signs of acute electrolyte problems appear. These symptoms can include confusion, seizures, unusual muscle weakness, or severe dizziness, as they may indicate hypernatremia (salt toxicity) according to official safety documentation.


Q: Why is Rehydron often recommended when traveling?

Oral Rehydration Salts (ORS) are commonly recommended by major international health organizations for inclusion in a travel health kit. This recommendation is based on the product’s recognized role in treating acute gastroenteritis, often known as Traveler's Diarrhea, which is a common cause of fluid loss abroad.


Q: Is it true that Rehydron may be useless in case of very severe vomiting?

Regulatory information states that oral treatment is considered inappropriate in conditions of severe, protracted (long-lasting) vomiting. In these situations, oral administration is not advised because the patient may require intravenous fluid therapy to address severe dehydration.


Q: Why must Rehydron solution be prepared only before use?

Official preparation guidelines state the solution should be made immediately before consumption to ensure it maintains its therapeutic integrity and efficacy. Once the powder is dissolved, the solution has a specific shelf life—typically 24 hours when refrigerated—after which it must be discarded to prevent contamination or degradation.


Q: Why is it important to continue drinking water when taking Rehydron?

Regulatory information indicates that the oral rehydration solution is complementary to, rather than a replacement for, normal fluid intake. Official health guidance states that patients, especially children and infants, should continue to receive normal feeding in addition to the ORS.


Q: Does food intake affect the absorption of Rehydron?

Official preparation guidance notes that the solution is typically used between meals, rather than concurrently with large amounts of solid food. Additionally, liquids high in fat or simple carbohydrates, such as juices or broth, should be avoided during administration, as they can disrupt the required osmolality and potentially worsen diarrhea.


Q: Can Rehydron replace all necessary fluids?

The solution is not intended to be a total substitute for all necessary liquid intake. While the product is highly effective at compensating for lost electrolytes and fluid volume, official guidance indicates it should be used in addition to a patient's normal diet and fluid consumption.


Q: Can Rehydron cause bloating?

While regulatory documents list adverse effects, bloating or abdominal distension is not officially listed as an adverse effect for this product. However, it is noted that abdominal pain has been reported as a potential reaction associated with other similar oral rehydration products in clinical trials.


Q: How does Rehydron differ from sports isotonic drinks?

Regidron, as an Oral Rehydration Salt (ORS), is specifically formulated according to WHO standards for treating illness-related dehydration. ORS contains a specified, often lower, amount of glucose compared to many commercial sports drinks, and adheres to a precisely balanced electrolyte ratio.

--OE

Q: Why do some people complain about a dry mouth after taking Rehydron?

Experiencing a dry mouth is officially listed as one of the signs of continued or residual fluid and electrolyte problems in patients using oral rehydration therapy. If this feeling persists, official patient information suggests it may be a sign of continued fluid and electrolyte imbalance.


Q: Is a prescription required to buy Rehydron?

The product is generally categorized as an Oral Rehydration Salt (ORS) for the treatment of mild to moderate dehydration. Consistent with this classification, it is often available for purchase without a prescription in many jurisdictions.


Q: Can Rehydron be used for dehydration prevention?

Official regulatory indications for the product cover both the treatment of existing dehydration and the prevention of dehydration when ongoing fluid loss, such as persistent diarrhea, is occurring.


Q: What is the osmolarity of Rehydron, and why is it important?

Official product information specifies the osmolarity of the solution. This concentration is critical because it directly influences the optimal rate of water and electrolyte absorption in the intestinal tract.


Q: Why is metabolic alkalosis mentioned as a contraindication in the instructions?

Metabolic alkalosis is officially listed as a contraindication for the solution. This is because the citrate component is designed to correct metabolic acidosis (excess acidity), and administering it during a state of alkalosis is avoided because it could potentially worsen the existing acid-base imbalance.


Q: Does Rehydron contain artificial colors or flavorings?

Standard Oral Rehydration Solutions aligned with core WHO criteria often exclude non-essential additives like artificial colors or excessive flavorings. The product focuses on the essential active ingredients, and the specific list of inactive ingredients should be consulted for full details.


Q: Can Rehydron be used with a high fever?

Fever is not an absolute contraindication for the oral rehydration solution, and treatment may continue as necessary to address fluid loss. However, if a high temperature is severe or persistent, consultation with a healthcare professional is important.

How should Регидрон be stored and disposed of?

How to Store and Dispose of Regidron

The storage conditions for the unopened Regidron powder require it to be kept at a temperature not exceeding 25 C in a dry place protected from light. The product must be stored out of the sight and reach of children as a safety measure.


Stability of the Prepared Solution

Once the powder is reconstituted with water, the resulting oral solution must be stored in a refrigerator at a temperature between 2 C and 8 C. The prepared solution is stable for 24 hours, and any unused portion must be discarded after this period.

Disposal of Waste

Official regulatory guidance mandates that any expired or unused medicinal product, or waste material, must be disposed of in accordance with local pharmaceutical waste handling requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Регидрон found in:

A-Z Index: